1	Defective monocyte enzymatic function and an inhibitory immune phenotype in HIV-
2	exposed uninfected African infants in the era of anti-retroviral therapy
3	Louise Afran <sup>1,2,3</sup> , Kondwani C. Jambo <sup>1,3</sup> , Wilfred Nedi <sup>1</sup> , David JC Miles <sup>1,4</sup> , Anmol Kiran <sup>1,7</sup> , Dominic
4	H Banda <sup>1</sup> , Ralph Kamg'ona <sup>1</sup> , Dumizulu Tembo <sup>1</sup> , Annette Burger <sup>4</sup> , Eleni Nastouli <sup>6</sup> , Brigit Ferne <sup>6</sup> ,
5	Henry C Mwandumba <sup>1,3</sup> , Paul Moss <sup>4</sup> , David Goldblatt <sup>6</sup> , Sarah Rowland-Jones <sup>5</sup> , Adam Finn <sup>1</sup> , Robert S
6	Heyderman <sup>1, 6</sup>
7	
8	<sup>1</sup> Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of
9	Medicine, <sup>2</sup> Bristol Children's Vaccine Centre, Schools of Cellular & Molecular Medicine and of
10	Population Health Sciences, University of Bristol, Bristol, United Kingdom, <sup>3</sup> Department of Clinical
11	Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom, <sup>4</sup> University of
12	Birmingham, Birmingham, United Kingdom, <sup>5</sup> University of Oxford, Nuffield Department of
13	Medicine, Oxford, United Kingdom, and <sup>6</sup> University College London, Division of Infection and
14	Immunity, United Kingdom, and <sup>7</sup> University of Edinburgh, United Kingdom
15	
16	Correspondence to: *Louise Afran, Malawi-Liverpool-Wellcome Trust Clinical Research Programme,
17	P.O Box 30096, Chichiri, Blantyre 3, Malawi. Email: Lafran@mlw.mw
18	Tel: +0992118817, +447762367111
19	or Robert S Heyderman, Division of Infection and Immunity University College London, Rayne
20	Building, 5 University Street, London, WC1E 6JF. Email: <u>r.heyderman@ucl.ac.uk</u>
21	Tel: +44 2031087665
22	
23	Keywords. HIV-exposure, immune dysregulation, monocyte function, neonatal vaccine
24	immunity, HIV-1, ART, Human herpes virus,
25	
26	Summary. HIV-Exposed Uninfected (HEU) infants are a rapidly expanding population in
27	NOTES This preprint reports new research that has not been certified by peer review and should not be used to quide clinical practice. SUD-Saharan Africa and are in gift y susceptible to disease caused by encapsulated bactel fain

28 the first year of life. The mechanism of this increased risk is still poorly understood. We 29 therefore investigated if HIV exposure dysregulates HEU infant immunity and if this is amplified by human herpes virus infection (HHV). Here, we compared monocyte enzymatic 30 31 function, innate and adaptive immune cell phenotype, and vaccine-induced antibody 32 responses between HEU and HUU infants. We demonstrate altered monocyte phagosomal 33 function and B cell subset homeostasis, and lower vaccine-induced anti-Haemophilus 34 influenzae type b (Hib) and anti-Tetanus Toxoid (TT) IgG titers in HEU compared to HUU 35 infants. There was no difference in the prevalence of HHV infection between HEU and HUU 36 infants. Our findings suggest that even in the era of antiretroviral therapy (ART)-mediated 37 viral suppression, HIV exposure dysregulates monocyte and B cell function during a vulnerable period of immune maturation in infancy. This may contribute to the high rates of 38 39 invasive bacterial disease and pneumonia in HEU infants.

#### 40 Introduction

41	HIV-exposed uninfected (HEU) infants are more susceptible to infection-related morbidity
42	and mortality <sup>1,2</sup> . HEU infants are particularly vulnerable to invasive bacterial disease <sup>3–7</sup>
43	particularly, pneumonia <sup>8–13</sup> and diarrhea <sup>14,15</sup> , they have more frequent hospitalisations, more
44	severe infections and increased risk of treatment failure. However, the mechanism of this
45	increased vulnerability remains unknown. The global population of children who are HEU is
46	substantial, estimated at 1.2 million births annually, mainly within developing countries <sup>16</sup> . A
47	coordinated strategy is therefore necessary to ensure their optimal health and wellbeing <sup>17</sup> .
48	
49	The vulnerability of HEU infants is a likely complex intersection of HIV-exposure immune
50	profile 'remodelling', an 'inflammatory' maternal cytokine milieu <sup>18</sup> , time of antiretroviral
51	therapy (ART) initiation <sup>19</sup> , ART use <sup>20</sup> and prophylactics <sup>21</sup> , increased exposure to maternal
52	viral and bacterial pathogens, and host microbial and environmental factors. Together these
53	result in a more permissive state for the development of infections <sup>1</sup> . Many observational
54	studies have reported immunological abnormalities in HEU infants <sup>22</sup> including highly
55	differentiated T-cells <sup>23–29</sup> and B-cell subsets <sup>30</sup> , altered responses to vaccines <sup>31–33</sup> , functional
56	impairment of natural killer cells <sup>34</sup> and monocytes <sup>35–37</sup> . Furthermore, few studies have
57	considered early transmission of immunomodulatory human herpes virus' (HHVs),
58	cytomegalovirus (CMV) <sup>38</sup> and Epstein Barr virus (EBV) <sup>39</sup> recrudescence during pregnancy
59	on HEU immunity. HHVs are important as they are implicated in delayed growth <sup>40,41</sup> , poor
60	neurodevelopment, altered mitochondria DNA <sup>42</sup> and inflammation in HEU infants <sup>43,44</sup> .
61	
62	Due to the successful HIV test and treat strategy globally, the prevalence of individuals
63	receiving ART has risen considerably <sup>16</sup> . Consequently, the number of HEU infants born to

64 mothers receiving ART has increased markedly <sup>45,46</sup>, but despite expanded maternal use of

65	ART <sup>47</sup> or implementation of prevention-of-mother-to-child-transmission (PMTCT)
66	programmes <sup>48</sup> , the risk of infection-related morbidity and mortality among HEU infants
67	remains high <sup>2</sup> , particularly the risk of encapsulated bacterial infection <sup>7,9,49–51</sup> . The immune
68	profile amongst HEU infants in this context is not well documented. We have therefore
69	addressed the question of whether HIV exposure and HHVs dysregulate infant immunity
70	and/or response to primary vaccination. By comprehensive cellular and serological
71	assessment, we show impaired monocyte phagosomal function, altered B cell homeostasis
72	and selective impairment of vaccine-induced anti-Hib antibody response in HEU babies less
73	than 6 months of age. These findings suggest acquired defects in innate and adaptive
74	immunity, heightened regulation of HEU immune responses, which may increase
75	susceptibility to invasive bacterial disease and pneumonia.
76	
77	Results
77 78	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV
77 78 79	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort
77 78 79 80	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant
77 78 79 80 81	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant cohort comprised 43 HIV-infected and 61 HIV-uninfected mother-infant pairs, who were
77 78 79 80 81 82	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant cohort comprised 43 HIV-infected and 61 HIV-uninfected mother-infant pairs, who were followed at 3 timepoints, 5-9, 14-15 and 18-23 weeks of age, corresponding to the Malawian
<ol> <li>77</li> <li>78</li> <li>79</li> <li>80</li> <li>81</li> <li>82</li> <li>83</li> </ol>	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant cohort comprised 43 HIV-infected and 61 HIV-uninfected mother-infant pairs, who were followed at 3 timepoints, 5-9, 14-15 and 18-23 weeks of age, corresponding to the Malawian routine infant vaccine schedule of: BCG at birth, then pentavalent vaccine at 6, 10 and 14
<ol> <li>77</li> <li>78</li> <li>79</li> <li>80</li> <li>81</li> <li>82</li> <li>83</li> <li>84</li> </ol>	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant cohort comprised 43 HIV-infected and 61 HIV-uninfected mother-infant pairs, who were followed at 3 timepoints, 5-9, 14-15 and 18-23 weeks of age, corresponding to the Malawian routine infant vaccine schedule of: BCG at birth, then pentavalent vaccine at 6, 10 and 14 weeks.
<ol> <li>77</li> <li>78</li> <li>79</li> <li>80</li> <li>81</li> <li>82</li> <li>83</li> <li>84</li> <li>85</li> </ol>	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant cohort comprised 43 HIV-infected and 61 HIV-uninfected mother-infant pairs, who were followed at 3 timepoints, 5-9, 14-15 and 18-23 weeks of age, corresponding to the Malawian routine infant vaccine schedule of: BCG at birth, then pentavalent vaccine at 6, 10 and 14 weeks.
<ol> <li>77</li> <li>78</li> <li>79</li> <li>80</li> <li>81</li> <li>82</li> <li>83</li> <li>84</li> <li>85</li> <li>86</li> </ol>	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant cohort comprised 43 HIV-infected and 61 HIV-uninfected mother-infant pairs, who were followed at 3 timepoints, 5-9, 14-15 and 18-23 weeks of age, corresponding to the Malawian routine infant vaccine schedule of: BCG at birth, then pentavalent vaccine at 6, 10 and 14 weeks.
<ol> <li>77</li> <li>78</li> <li>79</li> <li>80</li> <li>81</li> <li>82</li> <li>83</li> <li>84</li> <li>85</li> <li>86</li> <li>87</li> </ol>	Results Participant characteristics. We recruited two cohorts to evaluate the impact of HIV exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant cohort comprised 43 HIV-infected and 61 HIV-uninfected mother-infant pairs, who were followed at 3 timepoints, 5-9, 14-15 and 18-23 weeks of age, corresponding to the Malawian routine infant vaccine schedule of: BCG at birth, then pentavalent vaccine at 6, 10 and 14 weeks.

count of 294 (range 8-892) and were more likely to have had an elective caesarean birth,
compared to HIV-uninfected pregnant women (Table 1).

92 In the longitudinal infant cohort, HIV-infected mothers had received option B+ for an

93 average of 9.28 (range 1-72) months at the time of enrollment and had a mean nadir CD4+ T-

94 cell count of 409 (range 159-823). There was no difference between maternal age or

95 breastfeeding status but mode of delivery was more often caesarean section in HIV-infected

96 mothers compared to HIV-negative mothers (Table 1).

97

98 Impaired CD14<sup>+</sup> monocyte function in HEU new-borns. Monocytes are an important first 99 line of defence against invasive bacteria, particularly in early life, before the maturation of adaptive immunity 52,53 and are crucial in controlling bacterial pneumonia 54-56. We used a 100 flow cytometry-based whole blood reporter bead assay<sup>57</sup> to assess monocyte function in cord 101 102 blood (Figure 1a-b; Supplementary Figure 1). First, we assessed the ability of monocytes to 103 internalise Alexa Fluor 405-labeled IgG-coated reporter beads at 1 hour post co-incubation, 104 as a proxy of uptake capacity. We showed that the proportion of monocytes that internalised 105 reporter beads was similar between HEU infants and HUU controls (Figure 1c). Second, we 106 assessed the phagosomal superoxide burst activity, an important component of intracellular killing by phagocytes <sup>58</sup>, and found that phagosomal superoxide burst activity was lower in 107 108 monocytes from HEU infants compared to HUU controls (Figure 1d). Third, we assessed the 109 phagosomal bulk proteolytic activity, an important intracellular protein degradation mechanism that impacts antigen-presentation <sup>59</sup>, and showed that the phagosomal bulk 110 111 proteolytic activity was lower in monocytes from HEU infants compared to HUU controls 112 (Figure 1e). Collectively, these data indicate altered monocyte phagosomal functional 113 capacity at birth in HEU new-borns.

114

### 115 Inhibitory B cell phenotype and reduced T cell mitogen response in HEU new-borns. Having demonstrated altered monocyte phagosomal function which is part of innate 116 117 immunity in HEU new-borns, we next sought to investigate whether B and T cell subsets are 118 dysregulated. In the B cell compartment, we observed similar distributions of B cell subsets 119 between HEU and HUU new-born babies, including, CD10<sup>-</sup>CD21<sup>+</sup>CD27<sup>-</sup> (naive), CD10<sup>-</sup> 120 CD21<sup>-</sup>CD27<sup>+</sup> (resting memory), CD10<sup>-</sup>CD21<sup>+</sup>CD27<sup>+</sup> (activated memory), CD10<sup>-</sup>CD21<sup>-</sup> 121 CD27<sup>-</sup> (tissue-like memory) and CD10<sup>+</sup>CD27<sup>-</sup> (immature transitional) B cells (Figure 2a). 122 However, we found a higher proportion of Fc-receptor like 4 (FcRL4<sup>+</sup>) expressing B cells in 123 HEU new-borns, but no statistically significant differences in the proportion of PD-1 or 124 CD95-expressing B cells, when compared to HUU controls (Figure 2b). FcLR4<sup>+</sup> inhibits B 125 cell activation through the B cell receptor (BCR) and is a marker of B cell exhaustion in chronically HIV-infected adults <sup>60</sup>, which suggests increased B cell regulation in HEU new-126 born babies<sup>61</sup>. 127

128

129 In the T cell compartment, we found that the proportion of naïve and memory, CD4+ and 130 CD8+ T cell subsets were similar between HEU new-borns and HUU controls (Figure 3a-b). 131 There were also no differences between the two groups in the proportion of CD57 or PD-1-132 expressing CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Figure 3c-d), which are classical markers of T cell 133 immune senescence and exhaustion in chronic HIV infection<sup>62,63</sup>. IFNy production in 134 response to tuberculin purified protein derivative (PPD) in an 18-hour ELISpot assay was 135 similar in HEU new-borns compared to controls. In this population BCG is received soon 136 after birth. However, IFNy production in response to the selective T cell mitogen phytohemagglutinin (PHA)<sup>64</sup> was reduced in HEU new-borns compared to controls (figure 137 138 3e), indicating selective regulation of T-cell responses.

1	3	Q
1	$\mathcal{I}$	/

#### 140 **Persistent dysregulation of the B cell compartment in HEU infants.**

- 141 Having found an altered innate compartment and increased regulatory B cell phenotype at
- 142 birth, we then investigated the impact of HIV exposure on adaptive immunity in the first few
- 143 months of life in the longitudinal infant cohort. We found that the proportions of immature
- 144 transitional and tissue-like memory B cells were lower in HEU infants than HUU controls
- 145 (Figure 4a), two B cell subsets that are selectively dysregulated in HIV infection <sup>65,66</sup>.
- 146 However, as seen in the new-born cohort, the proportions of naïve and memory, CD4+ and
- 147 CD8+ T cell subsets, were similar between HEU infants and HUU controls (Figure 4a-b).
- 148

#### 149 Increased IFNy production to PPD in a T-cell ELISpot assay in HEU infants

- 150 To determine if T-cell responses were altered in HEU infants, we evaluated IFNγ spot
- 151 forming cells (SFCs) to tetanus toxoid (TT), hepatitis B (Hb) and purified protein derivative
- 152 (PPD) in an 18-hour T-cell ELIspot in infants aged 5-9 weeks of age. We observed increased
- 153 IFNy SFCs/million PBMCs to PPD amongst HEU infants compared to HUU controls, but
- 154 similar Hb, TT and PHA responses between the two groups (Supplementary figure 5a). These
- 155 data indicate that HEU infants' antigen-specific responses to PPD following BCG
- 156 vaccination at birth have the potential to be greater in capacity than HUU infants.
- 157

#### 158 Impaired IgG antibody responses to routine pentavalent vaccination in HEU infants. In

the longitudinal infant cohort, having demonstrated B-cell dysregulation, we interrogated

- 160 vaccine-induced memory B cell antibody responses to polysaccharide and protein antigens
- 161 that are in the Malawian infant primary vaccination series. This included PCV13 and
- 162 Pentavalent Vaccine (DPT-HepB-Hib) which protect against several important infant disease-
- 163 causing bacteria, we focused on: *Streptococcus pneumoniae* (13 serotypes) and *Haemophilus*

*influenza* type b (Hib), *Clostridium tetani* (tetanus toxoid) and *Corynebacterium diphtheriae*(diphtheria toxoid).

166

- 167 Following 3 vaccine doses, we found lower anti-*Hib* and anti-diphtheria toxoid (DT) titers,
- 168 but similar anti-TT titers in HEU infants, compared to HUU controls (Figure 5a-c). In the
- 169 mothers of these infants, anti-Hib IgG and anti-TT IgG titres but not anti-DT titers were
- 170 lower in HIV-infected mothers than HIV-uninfected controls (Figure 5d-f).
- 171 Having shown the B cell compartment produces differential antigen specific
- 172 immunoglobulins to vaccine antigens, we next tested whether HIV exposure influences the
- 173 levels of vaccine-induced functional antibody. Using a Multiplex
- 174 Opsonophagocytosis Assay (MOPA), we measured opsonophagocytic activity of 13 vaccine
- 175 serotypes from the PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in infant sera.
- 176 We found no difference in the geometric mean opsonophagocytic index (GMOI) of 13
- 177 pneumococcal serotypes and geometric mean concentration (GMC) of serotype-specific IgG
- 178 titres, between HEU infants and HUU controls (Table 2).
- 179

#### 180 Evidence of HIV exposure in early infancy

181 Next, we sought to ascertain evidence of HIV exposure as a driver of dysregulation in innate

and adaptive immunity of HEU new-borns by measuring HIV specific responses from birth

183 to infancy. We measured HIV Gag-specific responses in peripheral blood mononuclear cells

- <sup>67</sup> using an 18-hour *ex-vivo* IFN-γ ELISpot assay in both the HEU new-born and the
- 185 longitudinal infant cohorts. (Figure 6a; Supplementary Figure 3a) <sup>68–70</sup>. Few Gag-specific
- 186 responses were detectable in cord blood of HEU new-borns (Supplementary Figure 5).
- 187 Consistent with previous studies <sup>71,72</sup>, there was detectable IFN-γ producing HIV Gag-

188 specific cell responses in approximately 50% of the longitudinal cohort of HEU infants

189 (Figure 6b).

190

#### 191 HEU infants have increased exposure to maternal-derived hCMV

192 HEU infants are more frequently exposed to human herpes viruses (HHV) in utero and/or

193 perinatally than HUU infants <sup>73,74</sup>, due to the high seroprevalence and reactivation of hCMV

and EBV in HIV-infected individuals and pregnant women <sup>75–80</sup>. We therefore sought to

195 determine the extent of immune-modulating HHV, hCMV and EBV infection in our

196 longitudinal infant cohort.

197

We found that anti-hCMV IgG titers were higher in sera from HEU infants than HUU 198 199 controls (Figure 6c), but hCMV PCR detection was similar (Figure 6d), indicating potential 200 differences in the pattern of exposure to hCMV but not increased infection. We then 201 measured hCMV in maternal breastmilk as a potential source of transmission or transfer of 202 viral products to the infants. We found that the proportion of mothers with an hCMV positive 203 PCR result in breast milk was higher in the HIV-infected mothers compared to HIV-204 uninfected controls (Figure 6e). In contrast, we did not observe any statistically significant 205 differences between potential EBV exposure in HEU infants compared to HUU controls, whether by EBV IgG ELISA (Figure 6f) or PCR (Figure 6g). Overall, these results 206 207 demonstrate that HHV (hCMV and EBV) infection are common in infancy, irrespective of 208 HIV-exposure status. High hCMV titres in HEU infants may indicate immune boosting from 209 breastmilk of HIV-infected women.

210

#### 211 Discussion

9

212 HIV-exposed but uninfected infants are at an increased risk of a wide variety of infections 213 even in the era of universal access to maternal ART, but the underlying immunological basis 214 is not well understood <sup>7,51</sup>. We show altered monocyte phagosomal function, dysregulated B 215 cell homeostasis and selective impairment of vaccine responses in HEU infants within the 216 first 6 months of life. We also demonstrate evidence of HIV exposure and increased 217 likelihood of hCMV exposure in HEU infants. HIV and hCMV are immunomodulatory 218 viruses <sup>81</sup>, so co-exposure to these two pathogens in early life may contribute to this immune 219 dysregulation. We postulate that the complexity, variable severity and/or persistence of this 220 immunological phenotype explain the variable clinical manifestations reported in HEU infants <sup>8,9,11,40,82–86</sup>, which may depend on the duration and intensity of exposure to HIV and 221 222 other infectious co-factors.

223

224 The impaired monocyte phagosomal function in HEU new-borns highlights their potential 225 vulnerability to bacterial infection before the primary immunisation series. Monocyte 226 bactericidal activity requires uptake, reactive oxygen species (ROS) formation and 227 phagosomes-lysosomes fusion resulting in inhibition, killing and degradation of internalised bacteria<sup>87,88</sup>. In our setting, the validated flow cytometer reporter assay of phagocyte function 228 229 which uses zymosan has shown poor immune function and superoxide burst activity in HIVinfected adults with active tuberculosis (TB)<sup>89</sup>. Monocyte functional impairment against 230 231 encapsulated bacteria has also been observed in "age-associated" inflammation, where monocyte-activating cytokines TNF- $\alpha$  and IL-6 are augmented <sup>90</sup>. Similarly, increased 232 233 monocyte inflammatory markers, including sTNF-RI, IL-6, IP-10, oxLDL and sCD14 are reported in HEU new-borns<sup>87</sup>; as well as enhanced pro-inflammatory cytokine secretion 234 235 following stimulation with diverse PAMPs at 6 weeks of age <sup>91</sup>. Moreover, recent PBMC 236 transcriptomic profiling in HEU infants at 1-2 years of age, revealed down-regulated genes

(LCN2, CAMP, HP, MMP8, BPI, LTF) associated with neutrophil function<sup>92</sup>. It is therefore 237 238 plausible that the observed impaired monocyte phagosomal function is a consequence of an inflammatory microenvironment in HEU infants, from an inflammatory maternal cytokine 239 240 milleau and/or exposure to HIV antigens that could explain their increased susceptibility to 241 bacterial infection including pneumonia<sup>14</sup>. 242 In line with the proposed inflammatory environment in HEU new-borns<sup>93</sup>, we observed high 243 proportions of FcLR4 expressing B cells. In HIV-infected adults, B cells expressing the 244 inhibitory receptor FcLR4 are over-represented, an 'exhausted' B cell phenotype, that 245 displays poor B cell receptor mediated activation and antigen-specific antibody production in chronic HIV infection <sup>60,94,95</sup>. Additionally, in HEU infants at 6 to 14 weeks of age, we 246 247 observed low proportions of tissue-like memory (TLM) and immature-transitional B-cell 248 subsets. TLM and immature transitional B cells are augmented in HIV-infected adults, occurring most profoundly during chronic HIV infection <sup>96,97</sup>. The contraction of atypical 249 250 memory B cells in HEU infants may be indicative of dysregulated B cell homeostasis <sup>98</sup>. 251 Importantly, our data presents evidence of increased exposure to HIV and hCMV in HEU 252 infants from maternal HIV and/or viral proteins, hCMV recrudescence and high PPD specific 253 IFNy, that may promote B cell dysregulation in the first 2 months of life. PPD responses are 254 shown to be increased in mycobacterium tuberculosis (Mtb) sensitised mothers, which may 255 explain our findings<sup>99</sup>, furthermore, others have described a bimodal response to BCG/PPD (high/low) in HEU infants in our setting<sup>100</sup>. Taken together, the mechanisms of B cell 256 257 dysregulation are likely distinct from those seen in chronic HIV infection (hypergammaglobulinaemia)<sup>101</sup>, due to the lack of replicative virus and preserved CD4 T-258

cells.

260

261 Altered B cell homeostasis is associated with impaired antibody responses during chronic HIV infection <sup>102–105</sup>. Consistent with this observation, HIV-infected mothers in our cohort 262 exhibited lower anti-Hib and anti-TT antibody titers than HIV-uninfected mothers. In 263 264 agreement with maternal titers, we observed low anti-Hib titers in HEU infants. It is known that HIV-infected children are at greater risk of vaccine failure compared to HIV-uninfected 265 children <sup>106–108</sup>. However, our observation is in contrast with studies conducted in South 266 Africa <sup>109</sup> and Uganda <sup>110,111</sup>, who reported robust anti-Hib and anti-DT antibody titers in 267 HEU infants. In our setting the Pentavalent Vaccine (DPT-HepB-Hib) was used, in South 268 269 Africa it was (DTP-Hib and DTaP-IPV/Hib)<sup>109</sup>, and in Uganda (aP-HibCV and DTwP/HBV/PRP-T) <sup>110,111</sup>. Differential vaccine immunogenicity is likely multifactorial, 270 271 influenced by persistent immune exposure to HIV proteins, the time to maternal ART use and the unique burden of infectious co-factors that likely contribute to a microenvironment of 272 273 pro-inflammation. Furthermore, HIV proteins are reported to cause aberrant binding to surface immunoglobulins <sup>112–115</sup>, which may interfere with specific antibody responses. 274 275 Consistent with previous observations <sup>116</sup>, we observed that a relatively large number of HEU infants mounted an IFN-y response following stimulation with HIV Gag, however we did not 276 detect IFN-y responses in HEU new-borns. Detection of HIV-specific T cell responses in 277 278 HEU infants was first described nearly 30 years ago <sup>71,72</sup>. Others have reported that HEU 279 infants have increased regulatory T cells (Tregs) that correlate with decreased T cell function <sup>29</sup> and have shown that depletion of Treg cells from the cord blood of HEU new-borns reveals 280 HIV-1-specific T responses <sup>116</sup>. We also observed poor IFN- $\gamma$  responses in cord blood of 281 282 HEU new-borns following stimulation with the T cell mitogen PHA (which crosslinks the 283 TCR and glycosylated surface proteins). Taken together, these data point towards HIV 284 exposure as a possible driver of increased regulation/inhibition of T cell activation at birth.

285

286 Our study has some limitations, including use of a surrogate assay to measure monocyte 287 function and the limited number of assays we could perform on each sample. Additionally, 288 our cohorts were too small to establish direct associations with immune dysregulation and 289 clinical presentation of disease. 290 291 In conclusion, we show altered monocyte phagosomal function, dysregulated B cell 292 homeostasis and selective impairment of vaccine antibody responses in HEU infants within 293 the first 6 months of life. This period of vulnerability likely contributes to increased 294 susceptibility to disease-causing bacteria that commonly cause life-threating illness such as

296

295

#### 297 Methods

pneumonia in HEU infants.

298 Study Design and population. The study was conducted in Southern Malawi, at Ndirande 299 Health Centre (NHC) (a primary healthcare facility in the city of Blantyre) and at Queen 300 Elizabeth Central Hospital (OECH) (a tertiary teaching hospital in the city of Blantyre). We 301 recruited the infant cohort in two contiguous groups that were followed longitudinally. The 302 first group were aged 5-9 weeks (pre-1<sup>st</sup> vaccine dose) who were followed up to age 14-15 303 weeks (post-2<sup>nd</sup> vaccine dose) and the second group were aged 14-15 weeks (post-2<sup>nd</sup> vaccine dose) who were followed up to 18-23 weeks of age (post-3<sup>rd</sup> vaccine dose). We recruited 304 305 pregnant women in the early stages of labour at QECH maternity ward and subsequently their 306 babies at birth (termed birth cohort). Participating mothers were healthy, asymptomatic adults 307 (>18 yr) comprising HIV-infected and HIV-uninfected volunteers. HIV testing was 308 performed on whole blood using two commercial point-of-care rapid HIV test kits, 309 Determine HIV 1/2 kit (Abbott Diagnostic Division, Abbott Park, IL) and Unigold HIV 1/2 310 kit (Trinity Biotech Inc., Bray, Ireland). HIV-infected participants received first line ART

311 (Option B+ (Lamivudine, Tenofovir DF and Efavirenz (3TC/TDF/EFV)) at any point during 312 pregnancy and had a CD4+ T-cell count performed. All HEU babies received single dose 313 nevirapine at birth and co-trimoxazole until 6 months of age. Exclusion criteria for the study 314 participants were current or past history of smoking, heart disease, tuberculosis, high blood 315 pressure, drug use, syphilis, severe anaemia (haemoglobin <8 g/dl), placental abnormalities, 316 infant death and existing comorbidities. All babies received Bacille Calmette Guerin (BCG) 317 vaccine at birth. Written informed consent was obtained from all participants prior to 318 recruitment. Ethical approval was obtained from the University of Malawi College of 319 Medicine Research and ethics committee (COMREC), Blantyre, Malawi, protocol numbers 320 P.11/11/1140, P.06/11/1088.

321

322 Sample collection and processing. To maximise the number of samples we were able to 323 collect from very young infants, we collected 5ml of venous blood from the infants, at 5-9, 324 14-15 and 18-23 weeks of age following attendance at the vaccination clinic for pentavalent 325 DPT-HepB-Hib immunisation. Participants who did not complete their vaccine course were 326 excluded from the analysis. From their mothers, 10ml of venous blood were collected only at 327 the first visit and 3mls of breastmilk at all three time points. We collected upto 40ml cord 328 blood from the umbilical vein into sodium heparinised tubes using a 50ml syringe from the 329 baby interface of the placenta immediately after birth. Whole blood was kept at RT for no 330 longer than 2 hours from collection to processing. Peripheral blood mononuclear cells were 331 isolated by density centrifugation. Diluted whole blood was layered on top of Histopaque 332 Ficoll gradient (Sigma-Aldrich, UK) at a ratio of 2:1 and centrifuged (900g, 24 °C for 30 333 minutes). The PBMC fraction was removed using a Pasteur pipette and washed immediately in HBSS (Sigma Aldrich, UK) by centrifugation (500g, 4 °C for 5 minutes). Cells were re-334 335 suspended in 2mL of complete media ((RPMI 1640 plus (Sigma-Aldrich, UK) with 10mM

336	HEPES (Sigma-Aldrich, UK), 1% v/v penicillin, 1% V/V streptomycin (Sigma Aldrich) and
337	2mM L-glutamine (Sigma-Aldrich, UK)), then agitated to ensure complete mixing and
338	counted using a haemocytometer with 1:10 trypan blue (Sigma Aldrich, UK) staining to
339	confirm viability. Plasma was separated by centrifugation at 1500rpm for 10 minutes,
340	aspirated, aliquoted and stored at -80 for later use. Breastmilk samples were collected by
341	hand expression, fractionated into lipid and aqueous phase and stored at -80. Due to
342	limitations in the volume of blood collectable from very young babies and limited cell
343	numbers, not all the assays were performed on samples obtained from every participant.
344	
345	HIV testing. New-borns and infants qualitative HIV DNA PCR tests were performed in
346	batches of 23. Total RNA was isolated from $0.5 \times 10^6$ cells using AMPLICOR HIV-1 DNA
347	test, V1.5 (Roche, USA) according to the manufacturer's instructions.
348	Three HIV-RDT kits, from two separate manufacturers (Unigold <sup>™</sup> and Determine <sup>™</sup> ) were
349	used to confirm the presence or absence of HIV specific immunoglobulins (Ig) in maternal
350	peripheral blood. Cord blood mononuclear cells (CBMCs) from were stored in 500ul of
351	RNAlater and analysed at UCL by digital PCR as described elsewhere <sup>117</sup> .
352	
353	Maternal CD4 counts. Peripheral blood CD4 T-counts and full blood count (FBC) were
354	performed at the Malawi-Liverpool Wellcome Trust Clinical Research Programme
355	Diagnostic Laboratory on an Hmx analyser (Beckman Coulter, USA) using a standardized
356	protocol.
357	
358	Phenotypic analysis. Multicolour flow cytometry analysis was performed on whole blood
359	(WB). Samples were stained with the following fluorochrome conjugated antibodies, anti-
360	CD14 Phyocoerythrin Cyanine-7 (PECy7), anti-CD3 Allophycocyanin-H7 (APC-H7), anti-

15

361	CD4 Pacific Blue (PB), anti-CD8 Fluorescein (FITC), anti-CD8 (PECY7), CD45RA
362	Phyocoerythrin (PE), CD45RA PECY5, CCR7 Allophycocyanin (APC), anti-CD19 (APC),
363	anti-CD19 Peridinin-Chlorophyll-Protein (PERCP), anti-CD27 (PE), , CD10 PE-Cy7, CD21
364	FITC, CD27 APC-Cy7, CD95 e450, FcLR4 PE, CD57 FITC, PD-1 APC, PD-1 PE
365	(Supplementary Tables 1 and 2, Gating strategy supplementary figure 2). Samples were
366	acquired on Beckman Coulter Cyan ADP and analyses were performed using FlowJo Version
367	7.6.5 and 10.5 software (Treestar).

368

369 Measurement of monocyte phagosomal enzymatic activity. Phagosomal oxidative burst 370 and bulk proteolytic function in monocytes was measured using a flow cytometry-based reporter bead assay as described previously<sup>57,118,119</sup>. Briefly, 3µm diameter silica beads were 371 372 derivatized with the calibration fluorochrome (Alexa Fluor 405-SE) and the fluorogenic 373 reporter substrates Oxyburst Green succinimidyl ester (Oxybeads) (Molecular Probes, 374 Eugene, OR) for superoxide burst, or DQ Green bovine serum albumin (DQ-beads) 375 (Molecular Probes, Eugene, OR) for bulk proteolysis. When the beads are internalised by 376 monocytes the fluorescence intensity is proportional to the degree of activity in the 377 phagosome, which provided a readout of phagosomal enzymatic activity. The readout for the 378 assay is reported as the ratio of the median fluorescent intensity of the reporter fluorochrome 379 at 60mins:10mins and 240mins:10mins for oxidative burst and bulk proteolysis, respectively. 380 The uptake cut-off was 35% in the assay.

381

382 **T cell IFN** $\gamma$  **ELISpot**. 2x10<sup>6</sup> PBMCs were stimulated in an 18-hour IFN- $\gamma$  T cell ELISpot;

383 plates were coated with purified anti-human interferon-γ monoclonal antibody (αhuman-

384 IFN-γ-mAb) 1-D1K (Mabtech, UK) 1:66 at a concentration of 3.78µg/mL in sterile PBS. The

385 enumerated IFN-γ producing cells after antigen stimulation were used as an index of effector

memory T cell responses, as previously described <sup>120</sup>. Data were reported after deducting 2x
the value of the negative well. Stimulating antigens were: Phaseolus vulgaris lectin (PHA)
5ug/ml (NIBSC, UK), purified protein derivative (PPD) 10ug/ml (Statens serum institute,
Denmark) and HIV-1 consensus C gag 15-mer peptides (GAG peptide) 10ug/ml (NIH AIDS,
USA)<sup>120</sup>

391

392Human cytomegalovirus PCR . Real time PCR was used to detect hCMV in HIV-infected393and uninfected maternal breast milk and plasma. The results were based on a standard curve394constructed using an in-house plasmid previously calibrated against quality controls for395molecular diagnostics and external quality assessment panels (Hamprecht et al. 1998). The396positive control was assessed again and an expected value of 2,500 copies seen with results397read on the ABI Prism 7500 (Thermofisher, UK). The amplification plot was assessed against398a standard slope range of -3.10 to -3.60 and a R<sup>2</sup> value > 0.9.

399

400 Detection of Cytomegalovirus specific IgG and IgM antibodies. hCMV specific IgM in 401 plasma was measured using a commercial ELISA kit (IBL International, Hamburg) according 402 to manufacturer's instructions. A semi-quantitative, in-house hCMV IgG assay was used at 403 the laboratories in the University of Birmingham, UK. Plasma was diluted 1/4 in a dilution in 404 a 1:1:1 mix of plasma from three healthy donors, the top concentration was assigned an 405 arbitrary unit of 1000. The unknown samples were related to the standard curve and a titre 406 calculated. Briefly, Nunc 96-well plates Maxisorb (Fisher Scientific # 442404) were coated 407 with 50µL UV activated hCMV-lysate (1:4000) and mock-lysate (1:4000) in carbonate-408 bicarbonate buffer pH 9.6 (sigma capsules), then covered with parafilm and incubated at 4°C 409 overnight in the fridge. The following day, plates were washed three times in 200µL (PBS + 410 0.05% Tween20), 100µL of samples were added 1:600 in dilution buffer (PBS + 1%BSA +

411	0.05% Tween20), blank dilution buffer, and standards, then incubated for 1h at room
412	temperature (RT). Plates were washed again three times, then $100\mu L$ of the secondary
413	antibody, anti-human IgG-HRP (1/8000 dilution in PBS+1% BSA+0.05% Tween20) goat
414	anti- human IgG (Southern Biotech #2040-05). Plates were incubated and washed again as
415	described, after which 100µL of tetramethyl benzidine (TMB-solution) (Tebu-Bio) was added
416	for 10 min at RT. The reaction was stopped with $100\mu$ L 1M HCl and plates were read at
417	405nm (Biotek instrument).
418	
419	Sandwich enzyme-linked immunosorbent assay to detect IgG specific to vaccine
420	antigens. In an in-house ELISA, TT or DT (both NIBSC, UK) were diluted to 0.5 Lf/mL or
421	Hib capsular polysaccharide 0.1µg/mL in 10 mL carbonate coating buffer (0.015 M Na <sub>2</sub> CO <sub>3</sub> ,
422	0.035 M NaHCO <sub>3</sub> pH9.6); 100 $\mu$ L per well of the solution was pipetted into a 96-well flat
423	bottom Maxisorp plate. Plates were incubated overnight at $4^{\circ}$ C then washed seven times with
424	PBS 0.05% Tween. 50 $\mu$ l goat anti-human alkaline phosphatase-conjugated secondary
425	antibodies (Southern Biotech, UK) were diluted to 1ug/mL in PBS 0.05% Tween 2% BSA
426	and added to each well. The plates were incubated for 1 h at 37 $^{\circ}$ C, then washed seven times
427	with PBS 0.05% Tween. 100 $\mu$ L of Sigma-fast p-nitrophenyl phosphate substrate was added
428	to each well (Sigma, UK). A standard curve was generated using a set of 2- fold dilutions of a
429	standard pooled serum (NIBSC, UK). Optical density was measured (without acid stopping
430	the reaction) after 10 min using an ELISA plate reader (Biotek, UK) set at 405nm and
431	SoftMax Pro software <sup>121</sup> .
432	
433	Multiplexed opsonophagocytosis killing assay and serotype-specific $IgG$ . Sera from 20
434	infants were sent on dry ice to the UCL Great Ormond Street Institute of Child Health (UCL;

435 United Kingdom). Infants had received 3 doses of Prevnar (PCV13) at 6, 10, and 14 weeks of

436	age. Sera were stored at $-20^{\circ}$ C until analysis. Analyses were performed at the World Health
437	Organization pneumococcal reference laboratory (University College London, United
438	Kingdom). Immunoglobulin G (IgG) serum concentrations specific for the 13 vaccine
439	serotypes (1, 3, 4, 5, 6 A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were measured using an
440	enzyme-linked immunosorbent assay (ELISA) after adsorption with cell-wall and 22F
441	polysaccharides to increase the assay specificity <sup>122</sup> . A standardized opsonophagocytic assay
442	(OPA) was used to measure functional antibodies against the same serotypes <sup>123</sup> . The OPA
443	titre was defined as the reciprocal of the lowest serum dilution that induces $\geq$ 50% bacterial
444	cell death compared to the assay control.

445

446 Statistical analysis. Statistical analysis and graphical presentation were performed using 447 Prism 7/8 (GraphPad Software, San Diego, USA) and Python (Python Software Foundation) 448 was used to calculate summary statistics. Demographic and clinical characteristics were compared using Mann-Whitney-U for continuous and Fisher's exact tests or  $\chi^2$  for discrete 449 variables. ELISpot data were reported as subtracted 2 x background. Serotype-specific 450 451 opsonophagocytic indexes (OIs) were reported using geometric means and 95% confidence 452 intervals. The OIs were classified as being positive or negative based on the current 453 recommended cut-off value of  $\leq 8$  (negative) and  $\geq 8$  (positive). Results are reported as 454 median and IQR as stated.

455

### 456 Acknowledgments

457 The authors are grateful to the participants for their willingness to participate in this study.

458 This work was supported by a studentship from the Franklin Adams Trust and a project grant

459 from the Wellcome Trust . The Malawi-Liverpool-Wellcome Trust Clinical Research

460 Programme was supported by a strategic award from the Wellcome Trust.

19

461

### 462 Author contribution

- 463 L.A. A.F, R.S.H, S.R.J, D.M contributed to study design. L.A, A.B, B.F, R.K, D.H.B, D.G,
- 464 P.M, D.M performed the experiments. W.N recruited and monitored the participants. L.A,
- 465 K.C.J analysis and interpretation. H.M, D.M, A.F., K.C.J, R.S.H, reviewing the manuscript
- 466 L.A, K.C.J, S.R.J, A.F, R.S.H, final approval.

467

- 468 **Competing interests**
- 469 The authors declare no competing interests.

470

#### 471 **References**

472	1.	Afran, L. et al. HIV-exposed uninfected children: a growing population with a
473		vulnerable immune system? Clin. Exp. Immunol. 176, 11–22 (2014).
474	2.	le Roux, S. M. et al. Infectious morbidity of breastfed, HIV-exposed uninfected infants
475		under conditions of universal antiretroviral therapy in South Africa: a prospective
476		cohort study. Lancet Child Adolesc. Heal. 4, 220–231 (2020).
477	3.	Slogrove, A. L., Goetghebuer, T., Cotton, M. F., Singer, J. & Bettinger, J. A. Pattern of
478		Infectious Morbidity in HIV-Exposed Uninfected Infants and Children. Front.
479		Immunol. 7, 164 (2016).
480	4.	Gompels, U. A. et al. Human Cytomegalovirus Infant Infection Adversely Affects
481		Growth and Development in Maternally HIV-Exposed and Unexposed Infants in
482		Zambia. Clin. Infect. Dis. 54, 434–42 (2012).
483	5.	Slyker, J. A. et al. The detection of cytomegalovirus DNA in maternal plasma is
484		associated with mortality in HIV-1-infected women and their infants. AIDS January
485		<b>23</b> , 117–124 (2009).
486	6.	Slyker, J. A. et al. Acute cytomegalovirus infection in Kenyan HIV-infected infants.
487		<i>AIDS</i> <b>23</b> , 2173–81 (2009).
488	7.	Dauby, N., Chamekh, M., Melin, P., Slogrove, A. L. & Goetghebuer, T. Increased
489		Risk of Group B StreptococcusInvasive Infection in HIV-Exposed but Uninfected
490		Infants: A Review of the Evidence and Possible Mechanisms. Front. Immunol. 7, 505
491		(2016).
492	8.	Izadnegahdar, R., Fox, M. P., Jeena, P., Qazi, S. A. & Thea, D. M. Revisiting
493		pneumonia and exposure status in infants born to HIV-infected mothers. Pediatr.

494 Infect. Dis. J. **33**, 70–2 (2014).

495	9.	Adler, C. et al. Severe Infections in HIV-Exposed Uninfected Infants Born in a
496		European Country. PLoS One 10, e0135375 (2015).
497	10.	Slogrove, A. L., Cotton, M. F. & Esser, M. M. Severe Infections in HIV-Exposed
498		Uninfected Infants: Clinical Evidence of Immunodeficiency. J. Trop. Pediatr. 56, 75-
499		81 (2010).
500	11.	Slogrove, A. et al. HIV-Exposed Uninfected Infants are at Increased Risk for Severe
501		Infections in the First Year of Life. J. Trop. Pediatr. 58, 505–508 (2012).
502	12.	McNally, L. M. et al. Effect of age, polymicrobial disease, and maternal HIV status on
503		treatment response and cause of severe pneumonia in South African children: a
504		prospective descriptive study. Lancet 369, 1440–1451 (2007).
505	13.	Kelly, M. S. et al. Treatment Failures and Excess Mortality Among HIV-Exposed,
506		Uninfected Children With Pneumonia. J. Pediatric Infect. Dis. Soc. 4, e117-26 (2015).
507	14.	Brennan, A. T. et al. A Meta-analysis Assessing Diarrhea and Pneumonia in HIV-
508		Exposed Uninfected Compared with HIV-Unexposed Uninfected Infants and Children.
509		Journal of Acquired Immune Deficiency Syndromes 82, 1–8 (2019).
510	15.	Singh, H. K. et al. High Rates of All-cause and Gastroenteritis-related Hospitalization
511		Morbidity and Mortality among HIV-exposed Indian Infants. BMC Infect. Dis. 11, 193
512		(2011).
513	16.	UNAIDS. Joint United Nations Programme on HIV/AIDS. (2019). Available at:
514		https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data. (Accessed:
515		31st December 2020)
516	17.	South, A. et al. Estimates of the global population of children who are HIV-exposed
517		and uninfected, 2000-18: a modelling study. Artic. Lancet Glob Heal. 8, 67–75 (2020).
518	18.	Sevenoaks, T. et al. Association of maternal and infant inflammation with

519		neurodevelopment in HIV-exposed uninfected children in a South African birth cohort.
520		Brain. Behav. Immun. (2020). doi:10.1016/j.bbi.2020.08.021
521	19.	Goetghebuer, T. et al. Initiation of Antiretroviral Therapy Before Pregnancy Reduces
522		the Risk of Infection-related Hospitalization in Human Immunodeficiency Virus-
523		exposed Uninfected Infants Born in a High-income Country. Clin. Infect. Dis. 68,
524		1193–1203 (2019).
525	20.	Van Dyke, R. B., Chadwick, E. G., Hazra, R., Williams, P. L. & Seage, G. R. The
526		PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to
527		Antiretroviral Drugs. Front. Immunol. 7, 23 (2016).
528	21.	D'Souza, A. W. et al. Cotrimoxazole prophylaxis increases resistance gene prevalence
529		and $\alpha$ -diversity but decreases $\beta$ -diversity in the gut microbiome of HIV-exposed,
530		uninfected infants. Clin. Infect. Dis. (2019). doi:10.1093/cid/ciz1186
531	22.	Goetghebuer, T., Rowland-Jones, S. L. & Kollmann, T. R. Editorial: Immune
532		Mechanisms Underlying the Increased Morbidity and Mortality of HIV-Exposed
533		Uninfected (HEU) Children. Front. Immunol. 8, 1060 (2017).
534	23.	de Deus, N. et al. Impact of elevated maternal HIV viral load at delivery on T-cell
535		populations in HIV exposed uninfected infants in Mozambique. BMC Infect. Dis. 15,
536		37 (2015).
537	24.	Longwe, H. et al. Proportions of CD4+, CD8+ and B cell subsets are not affected by
538		exposure to HIV or to Cotrimoxazole prophylaxis in Malawian HIV-uninfected but
539		exposed children. BMC Immunol. 16, 50 (2015).
540	25.	Kakkar, F. et al. Impact of maternal HIV-1 viremia on lymphocyte subsets among
541		HIV-exposed uninfected infants: protective mechanism or immunodeficiency. BMC
542		Infect. Dis. 14, 236 (2014).

543	26.	Kidzeru, E. B. et al. In-utero exposure to maternal HIV infection alters T-cell immune
544		responses to vaccination in HIV-uninfected infants. AIDS 28, 1421-30 (2014).
545	27.	Bunders, M. J. et al. Fetal exposure to HIV-1 alters chemokine receptor expression by
546		CD4+T cells and increases susceptibility to HIV-1. Sci. Rep. 4, 6690 (2014).
547	28.	Gabriel, B. et al. Analysis of the TCR Repertoire in HIV-Exposed but Uninfected
548		Infants. Sci. Rep. 9, (2019).
549	29.	Jalbert, E. et al. HIV-exposed uninfected infants have increased regulatory T cells that
550		correlate with decreased T cell function. Front. Immunol. 10, (2019).
551	30.	Nduati, E. W. et al. HIV-Exposed Uninfected Infants Show Robust Memory B-Cell
552		Responses in Spite of a Delayed Accumulation of Memory B Cells: an Observational
553		Study in the First 2 Years of Life. Clin. Vaccine Immunol. 23, 576-85 (2016).
554	31.	Mazzola, T. N. et al. Impaired Bacillus Calmette-Guérin cellular immune response in
555		HIV-exposed, uninfected infants. AIDS 25, 2079-87 (2011).
556	32.	Abramczuk, B. M. et al. Impaired Humoral Response to Vaccines among HIV-
557		Exposed Uninfected Infants. Clin. Vaccine Immunol. 18, 1406–1409 (2011).
558	33.	Reikie, B. A. et al. Antibody Responses to Vaccination among South African HIV-
559		Exposed and Unexposed Uninfected Infants during the First 2 Years of Life. Clin.
560		<i>Vaccine Immunol.</i> <b>20</b> , 33–38 (2013).
561	34.	Gasper, M. A. et al. Natural killer cell and T-cell subset distributions and activation
562		influence susceptibility to perinatal HIV-1 infection. AIDS 28, 1115–24 (2014).
563	35.	Simani, O. E. et al. Effect of in-utero HIV exposure and antiretroviral treatment
564		strategies on measles susceptibility and immunogenicity of measles vaccine. AIDS 27,
565		1583–1591 (2013).

- 566 36. Bunders, M. J. et al. Haematological parameters of HIV-1-uninfected infants born to
- 567 HIV-1-infected mothers. *Acta Pædiatrica* **94**, 1571–1577 (2005).
- 568 37. Reikie, B. A. et al. Altered innate immune development in HIV-exposed uninfected
- 569 infants. J. Acquir. Immune Defic. Syndr. 66, 245–55 (2014).
- 570 38. Evans, C. *et al.* CMV acquisition and inflammation in HIV-exposed uninfected
- 571 Zimbabwean infants. J. Infect. Dis. 215, jiw630 (2016).
- 572 39. Montoya-Ferrer, A. *et al.* Clinical and Biological Factors Associated With Early
- 573 Epstein-Barr Virus Infection in Human Immunodeficiency Virus–Exposed Uninfected
- 574 Infants in Eastern Uganda. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa161
- 575 40. Wedderburn, C. J. et al. Growth and Neurodevelopment of HIV-Exposed Uninfected
- 576 Children: a Conceptual Framework. *Current HIV/AIDS Reports* **16**, 501–513 (2019).
- 577 41. Evans, C. et al. Inflammation, cytomegalovirus and the growth hormone axis in HIV-
- 578 exposed uninfected Zimbabwean infants. *AIDS* (2020).
- 579 doi:10.1097/QAD.00000000002646
- 580 42. Jao, J. et al. Lower mitochondrial DNA and altered mitochondrial fuel metabolism in
- 581 HIV-exposed uninfected infants in Cameroon. *AIDS* **31**, 2475–2481 (2017).
- 582 43. Filteau, S. & Rowland-Jones, S. Cytomegalovirus infection may contribute to the
- 583 reduced immune function, growth, development, and health of HIV-exposed,
- 584 uninfected African children. *Frontiers in Immunology* **7**, 257 (2016).
- 585 44. Garcia-Knight, M. A. et al. Cytomegalovirus viraemia is associated with poor growth
- and T-cell activation with an increased burden in HIV-exposed uninfected infants.
- 587 *AIDS* **31**, 1809–1818 (2017).
- 588 45. WHO, G. program on A. *PREVENT HIV*, *TEST AND TREAT ALL WHO SUPPORT*
- 589 *FOR COUNTRY IMPACT*. (2016).

$\mathcal{O}$	590	46.	Mendez-Lopez	. A. et al.	Population	uptake and	effectiveness	s of test-and-	trea
---------------	-----	-----	--------------	-------------	------------	------------	---------------	----------------	------

- 591antiretroviral therapy guidelines for preventing the global spread of HIV: an ecological
- 592 cross-national analysis. *HIV Med.* **20**, 501–512 (2019).
- 593 47. Arikawa, S., Rollins, N., Newell, M.-L. & Becquet, R. Mortality risk and associated
- factors in HIV-exposed, uninfected children. *Trop. Med. Int. Heal.* 21, 720–734
  (2016).
- Brennan, A. T. *et al.* A meta-analysis assessing all-cause mortality in HIV-exposed
  uninfected compared with HIV-unexposed uninfected infants and children. *AIDS* 30,
  2351–60 (2016).
- 599 49. Epalza, C. *et al.* High Incidence of Invasive Group B Streptococcal Infections in HIV600 Exposed Uninfected Infants. *Pediatrics* 126, e631–e638 (2010).
- 50. Cools, P. *et al.* Role of HIV exposure and infection in relation to neonatal GBS disease
  and rectovaginal GBS carriage: a systematic review and meta-analysis. *Sci. Rep.* 7,
  13820 (2017).
- 604 51. Taron-Brocard, C. *et al.* Increased risk of serious bacterial infections due to maternal
- 605 immunosuppression in HIV-exposed uninfected infants in a European country. *Clin.*606 *Infect. Dis.* **59**, 1332–45 (2014).
- 607 52. Prosser, A. *et al.* Phagocytosis of neonatal pathogens by peripheral blood neutrophils
  608 and monocytes from new-born preterm and term infants. *Pediatr. Res.* 74, 503–510
  609 (2013).
- 610 53. Wong, K. L. *et al.* The three human monocyte subsets: Implications for health and
  611 disease. *Immunol. Res.* 53, 41–57 (2012).
- 612 54. Olliver, M., Hiew, J., Mellroth, P., Henriques-Normark, B. & Bergman, P. Human
  613 Monocytes Promote Th1 and Th17 Responses to Streptococcus pneumoniae. *Infect.*

- 614 *Immun.* **79**, 4210–4217 (2011).
- 615 55. Goto, Y. et al. Monocyte recruitment into the lungs in pneumococcal pneumonia. Am.
- 616 *J. Respir. Cell Mol. Biol.* **30**, 620–626 (2004).
- 617 56. Serbina, N. V., Jia, T., Hohl, T. M. & Pamer, E. G. Monocyte-mediated defense
- 618 against microbial pathogens. *Annual Review of Immunology* **26**, 421–452 (2008).
- 57. Jambo, K. C. *et al.* Small alveolar macrophages are infected preferentially by HIV and
  exhibit impaired phagocytic function. *Mucosal Immunol.* (2014).
- 621 doi:10.1038/mi.2013.127
- 622 58. Serbina, N. V., Jia, T., Hohl, T. M. & Pamer, E. G. Monocyte-Mediated Defense
- 623 Against Microbial Pathogens. Annu. Rev. Immunol. 26, 421–452 (2008).
- 59. Jutras, I. & Desjardins, M. Phagocytosis: At the Crossroads of Innate and Adaptive
  Immunity. *annualreviews.org* 21, 511–527 (2005).
- 626 60. Kardava, L. et al. Attenuation of HIV-associated human B cell exhaustion by siRNA
- 627 downregulation of inhibitory receptors. J. Clin. Invest. **121**, 2614–2624 (2011).
- 628 61. Musimbi, Z. D. et al. Peripheral blood mononuclear cell transcriptomes reveal an over-
- representation of down-regulated genes associated with immunity in HIV-exposed
  uninfected infants. *Sci. Rep.* 9, (2019).
- 631 62. Petrovas, C. *et al.* Differential association of programmed death-1 and CD57 with ex
  632 vivo survival of CD8+ T cells in HIV infection. *J. Immunol.* 183, 1120–32 (2009).
- 633 63. Landay, D. E. N. and A. L. Biomarkers of immune dysfunction in HIV. *curr opin hiv*634 *aids* 5, 175–180 (2013).
- 635 64. Abolfazl Movafagh, Heydary, H., Mortazavi-Tabatabaei, S. A. & Azargashb, E. The
  636 Significance Application of Indigenous Phytohemagglutinin (PHA) Mitogen on

637		Metaphase and Cell Culture Procedure - PubMed. Iran j pharm res (2011). Available
638		at: https://pubmed.ncbi.nlm.nih.gov/24250428/. (Accessed: 17th November 2020)
639	65.	Sciaranghella, G., Tong, N., Mahan, A. E., Suscovich, T. J. & Alter, G. Decoupling
640		activation and exhaustion of B cells in spontaneous controllers of HIV infection. AIDS
641		<b>27</b> , 175–80 (2013).
642	66.	Ho, J. et al. Two overrepresented B cell populations in HIV-infected individuals
643		undergo apoptosis by different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 103,
644		19436–41 (2006).
645	67.	Cox, J. H., Ferrari, G. & Janetzki, S. Measurement of cytokine release at the single cell
646		level using the ELISPOT assay. Methods 38, 274–282 (2006).
647	68.	Karlsson, A. C. et al. Comparison of the ELISPOT and cytokine flow cytometry
648		assays for the enumeration of antigen-specific T cells. J. Immunol. Methods 283, 141-
649		153 (2003).
650	69.	Tassignon, J. et al. Monitoring of cellular responses after vaccination against tetanus
651		toxoid: Comparison of the measurement of IFN- $\gamma$ production by ELISA, ELISPOT,
652		flow cytometry and real-time PCR. J. Immunol. Methods 305, 188-198 (2005).
653	70.	Meierhoff, G., Ott, P. A., Lehmann, P. V. & Schloot, N. C. Cytokine detection by
654		ELISPOT: Relevance for immunological studies in type 1 diabetes.
655		Diabetes/Metabolism Research and Reviews 18, 367–380 (2002).
656	71.	Rowland-Jones, S. L. L. et al. HIV-specific cytotoxic T-cell activity in an HIV-
657		exposed but uninfected infant. Lancet <b>341</b> , 860–861 (1993).
658	72.	Cheynier, R. et al. Cytotoxic T lymphocyte responses in the peripheral blood of
659		children born to human immunodeficiency virus-1-infected mothers. Eur. J. Immunol.
660		<b>22</b> , 2211–2217 (1992).

- 661 73. Adachi, K. et al. Cytomegalovirus Urinary Shedding in HIV-infected Pregnant
- Women and Congenital Cytomegalovirus Infection. *Clin. Infect. Dis.* **65**, 405–413
- 663 (2017).
- 664 74. Adachi, K. et al. Congenital Cytomegalovirus and HIV Perinatal Transmission.
- 665 *Pediatr. Infect. Dis. J.* **37**, 1016–1021 (2018).
- 666 75. Miles, D. J. C. *et al.* Cytomegalovirus Infection in Gambian Infants Leads to Profound
  667 CD8 T-Cell Differentiation. *J. Virol.* 81, 5766–5776 (2007).
- 668 76. Kaye, S. et al. Virological and Immunological Correlates of Mother-to-Child
- 669 Transmission of Cytomegalovirus in The Gambia. J. Infect. Dis. 197, 1307–1314
  670 (2008).
- 671 77. Mutalima, N. *et al.* Associations between Burkitt lymphoma among children in
  672 Malawi and infection with HIV, EBV and malaria: Results from a case-control study.
  673 *PLoS One* **3**, (2008).
- 674 78. Schaftenaar, E. *et al.* High seroprevalence of human herpesviruses in HIV-infected
  675 individuals attending primary healthcare facilities in rural South Africa. *PLoS One* 9,
  676 e99243 (2014).
- 677 79. Piriou, E. *et al.* Early age at time of primary Epstein-Barr virus infection results in
  678 poorly controlled viral infection in infants from Western Kenya: clues to the etiology
  679 of endemic Burkitt lymphoma. *J. Infect. Dis.* 205, 906–13 (2012).
- 680 80. Purtilo, D. T. & Sakamoto, K. Reactivation of Epstein-Barr virus in pregnant women:
- 681 social factors, and immune competence as determinants of lymphoproliferative
- diseases-a hypothesis. *Med. Hypotheses* **8**, 401–8 (1982).
- 683 81. Kourtis, A. P. *et al.* Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants
  684 of HIV-Infected Mothers in Malawi. *Clin. Vaccine Immunol.* 22, 1222–1226 (2015).

- 685 82. Deichsel, E. L. et al. Birth size and early pneumonia predict linear growth among HIV-
- 686 exposed uninfected infants. *Matern. Child Nutr.* **15**, (2019).
- 687 83. Chaudhury, S. et al. Neurodevelopment of HIV-Exposed and HIV-Unexposed
- 688 Uninfected Children at 24 Months. *Pediatrics* **140**, (2017).
- 689 84. Slogrove, A. L. *et al.* Surviving and Thriving-Shifting the Public Health Response to
- 690 HIV-Exposed Uninfected Children: Report of the 3rd HIV-Exposed Uninfected Child
- 691 Workshop. Front. Pediatr. 6, 157 (2018).
- 692 85. Zash, R. *et al.* HIV-exposed children account for more than half of 24-month mortality
- 693 in Botswana. *BMC Pediatr.* **16**, (2016).
- 694 86. Liu, H. et al. Characterization of human respiratory syncytial virus (RSV) isolated
- 695 from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during
- 696 2015-2017. Influenza Other Respi. Viruses 14, 403–411 (2020).
- 697 87. Amer, A. O. & Swanson, M. S. A phagosome of one's own: A microbial guide to life
  698 in the macrophage. *Current Opinion in Microbiology* 5, 56–61 (2002).
- 699 88. Fang, F. C. Antimicrobial reactive oxygen and nitrogen species: Concepts and
  700 controversies. *Nature Reviews Microbiology* 2, 820–832 (2004).
- 701 89. Gupta-Wright, A. et al. Functional Analysis of Phagocyte Activity in Whole Blood
- 702 from HIV/Tuberculosis-Infected Individuals Using a Novel Flow Cytometry-Based
- 703 Assay. Front. Immunol. 8, 1222 (2017).
- 90. Puchta, A. *et al.* TNF Drives Monocyte Dysfunction with Age and Results in Impaired
  Anti-pneumococcal Immunity. *PLOS Pathog.* 12, e1005368 (2016).
- 706 91. Reikie, B. A. *et al.* Altered innate immune development in HIV-exposed uninfected
  707 infants. *J. Acquir. Immune Defic. Syndr.* 66, 245–55 (2014).

- 708 92. Musimbi, Z. D. et al. Peripheral blood mononuclear cell transcriptomes reveal an over-
- representation of down-regulated genes associated with immunity in HIV-exposed
- 710 uninfected infants. Sci. Rep. 9, (2019).
- 711 93. Dirajlal-Fargo, S. et al. HIV-exposed-uninfected infants have increased inflammation
- 712 and monocyte activation. *AIDS* **33**, 845–853 (2019).
- Final Strategies Strateg
- 715 95. Moir, S. & Fauci, A. S. Insights Into B Cells And Hiv-Specific B-Cell Responses In
- 716 Hiv-Infected Individuals. *Immunol. Rev.* **254**, 207–224 (2013).
- 717 96. Malaspina, A., Moir, S., Ho, J., ... W. W.-P. of the & 2006, undefined. Appearance of
- 718 immature/transitional B cells in HIV-infected individuals with advanced disease:
- 719 correlation with increased IL-7. *Natl. Acad Sci.*
- 720 97. Malaspina, A. et al. Idiopathic CD4+ T lymphocytopenia is associated with increases
- in immature/transitional B cells and serum levels of IL-7. *ashpublications.org*
- Shah, H. B. *et al.* Insights from analysis of human antigen-specific memory B cell
  repertoires. *Frontiers in Immunology* 10, 3064 (2019).
- 724 99. Jones, C. E. *et al.* The impact of HIV exposure and maternal Mycobacterium
- tuberculosis infection on infant immune responses to bacille Calmette-Guérin
  vaccination. *AIDS* 29, 155–165 (2015).
- 100. Miles, D. J. C. et al. Human immunodeficiency virus (HIV) infection during
- 728 pregnancy induces CD4 T-cell differentiation and modulates responses to Bacille
- Calmette-Guérin (BCG) vaccine in HIV-uninfected infants. *Immunology* 129, 446–454
  (2010).
- 101. Moir, S. & Fauci, A. S. B cells in HIV infection and disease. Nat Rev Immunol 9, 235-

- 732 245 (2009).
- Abu-Raya, B., Smolen, K. K., Willems, F., Kollmann, T. R. & Marchant, A. Transfer
  of Maternal Antimicrobial Immunity to HIV-Exposed Uninfected New-borns. *Front. Immunol.* 7, (2016).
- Jallow, S., Cutland, C. L., Masbou, A. K., Adrian, P. & Madhi, S. A. Maternal HIV
  infection associated with reduced transplacental transfer of measles antibodies and
  increased susceptibility to disease. *J. Clin. Virol.* 94, 50–56 (2017).
- 104. Ray, J. E. et al. Reduced Transplacental Transfer of Antimalarial Antibodies in
- 740 Kenyan HIV-Exposed Uninfected Infants. *Open forum Infect. Dis.* **6**, ofz237 (2019).
- 105. Dzanibe, S. *et al.* Reduced transplacental transfer of group b streptococcus surface
- protein antibodies in HIV-infected mother-new-born dyads. J. Infect. Dis. 215, 415–
  419 (2017).
- 106. Cowgill, K. D. *et al.* Effectiveness of Haemophilus influenzae Type b Conjugate
  Vaccine Introduction Into Routine Childhood Immunization in Kenya. *JAMA J. Am. Med. Assoc.* 296, 671–678 (2006).
- 140 *Mea. Assoc.* **290**, 0/1–0/8 (2000).
- 107. Paul Dazaa Keystoxe Misoya, Agnes Katsulukuta, Bradford D. Gessner, Reggis
- 748 Katsande, Bekithemba R. Mhlanga, Judith E. Mueller, Christopher B. Nelson, Amos
- 749 Phiri, Elizabeth M. Molyneuxi, Malcolm E. Molyneuxh, R. B. *et al.* The impact of
- routine infant immunization with Haemophilus influenzae type b conjugate vaccine in
- Malawi, a country with high human immunodeficiency virus prevalence. *Vaccine* 24,
  6232–6239 (2006).
- Madhi, S. a *et al.* Immunogenicity and effectiveness of Haemophilus influenzae type b
  conjugate vaccine in HIV infected and uninfected African children. *Vaccine* 23, 5517–
  5525 (2005).

32

- 109. Jones, C. E. et al. Maternal HIV Infection and Antibody Responses Against Vaccine-
- 757 Preventable Diseases in Uninfected Infants. *JAMA* **305**, 576 (2011).
- 110. Simani, O. E. et al. Effect of HIV exposure and timing of antiretroviral therapy
- initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and
- 760 hepatitis B vaccines. *Expert Rev. Vaccines* **18**, 95–104 (2019).
- 761 111. Gaensbauer, J. T. et al. Impaired haemophilus influenzae type b transplacental
- antibody transmission and declining antibody avidity through the first year of life
- represent potential vulnerabilities for HIV-exposed but -uninfected infants. *Clin.*
- 764 *Vaccine Immunol.* **21**, 1661–7 (2014).
- 112. Chadburn, C. et al. CD40-Independent Mechanism Involving Switch Recombination
- through a HIV-1 Envelope Triggers Polyclonal Ig Class. *Am Assoc Immnol* (2020).
  doi:10.4049/jimmunol.176.7.3931
- 113. Silverman, G., Immunology, C. G.-N. R. & 2006, undefined. Confounding B-cell
  defences: lessons from a staphylococcal superantigen. *nature.com*
- 114. Rappocciolo, G. *et al.* DC-SIGN on B Lymphocytes Is Required For Transmission of
  HIV-1 to T Lymphocytes. *PLoS Pathog.* 2, e70 (2006).
- 115. Moir, S. et al. B cells of HIV-1-infected patients bind virions through CD21-
- complement interactions and transmit infectious virus to activated T cells. *J. Exp. Med.* **192**, 637–645 (2000).
- 116. Legrand, F. A. et al. Strong HIV-1-Specific T Cell Responses in HIV-1-Exposed
- 776 Uninfected Infants and Neonates Revealed after Regulatory T Cell Removal. *PLoS*777 *One* 1, e102 (2006).
- 117. Busby, E. *et al.* Instability of 8E5 calibration standard revealed by digital PCR risks
  inaccurate quantification of HIV DNA in clinical samples by qPCR. *Sci. Rep.* 7, 1209

780 (2017).

- 781 Yates, R. M., Hermetter, A. & Russell, D. G. The kinetics of phagosome maturation as 118. 782 a function of phagosome/lysosome fusion and acquisition of hydrolytic activity. 783 Traffic 6, 413–420 (2005). 784 Podinovskaia, M. et al. Dynamic quantitative assays of phagosomal function. Curr. 119. 785 Protoc. Immunol. 102, 14.34.1-14.34.14 (2013). 786 Kabilan, L. et al. Detection of intracellular expression and secretion of interferon-120. 787 gamma at the single-cell level after activation of human T cells with tetanus toxoid in 788 vitro. Eur J Immunol 20, 1085–9 (1990). 789 Engvall, E. & Perlmann, P. Enzyme-linked immunosorbent assay (ELISA). 121. 790 Quantitative assay of immunoglobulin G. Immunochemistry 8, 871–4 (1971). 791 Wernette, C. M. et al. Enzyme-linked immunosorbent assay for quantitation of human 122. 792 antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10, 514-9 793 (2003). 794 Rose, C. E. et al. Multilaboratory comparison of Streptococcus pneumoniae 123. 795 opsonophagocytic killing assays and their level of agreement for the determination of 796 functional antibody activity in human reference sera. Clin. Vaccine Immunol. 18, 135-797 42 (2011). 798 124. WHO. Weekly epidemiological record Relevé épidémiologique hebdomadaire. (2006). 799 WHO. Tetanus vaccines: WHO position paper - February 2017. 92, 53-76 (2017). 125. 800 WHO. Diphtheria vaccine: WHO position paper – August 2017. 92, 417–436 (2017). 126. 801
  - 802

803

#### 804 Tables

#### 805 Table 1. Participant characteristics among HEU new-borns, infants and HUU controls

806

	New-born Birth cohort			Longitudinal Infant cohort		
	HIV-	HIV+	p-value	HIV-	HIV+	p-value
<sup>a</sup> Mothers age in years	27.6 (23.6-	29 7(25 95-	0.86	21.9 (19.5-	28.8 (25.2-33.1)	0.37
women's age in years	27.0 (25.0-	29.7(23.95-	0.80	21.9 (19.3-	20.0 (23.2-33.1)	0.57
(IQR)	32.95)	32.2)		26.2)		
<sup>a</sup> Mothers ART no.(%)	N/A	34/34 (100)	-	N/A	37/43	-
					(86)	
<sup>a</sup> Mothers time on ART	N/A	18.17 (1-	-	N/A	9.28 (0-72)	-
months (range)		143)				
<sup>a</sup> Mothers CD4+ cells µL	N/A	294 (8-892)	N/A	N/A	409 (159-823)*	-
median (IQR)					*	
<sup>a</sup> Mothers no. caesarean	0/44 (0)	14/34 (39)	0.01	-	-	-
Section (%)						
	HUU	HEU	p-value	HUU	HEU	p-value
	new-born	new-born		infant	infant	*
<sup>a</sup> Female Sex of child	22/44	15/34	0.65	29/61 (55)	22/43 (39)	0.24
HIV DNA PCR test	-	31/34 (100)		-	43/43	-
result of child at birth						
HIV DNA PCR test	-	34/34 (100)		-	36/43 (83.7)*	-
result of child at 6						
weeks						

807

Abbreviations: IQR, interquartile range; No., number; %=percentage; µL= microliter; dPCR=digital PCR, RDT = rapid diagnostic test
performed on whole blood. \* Calculated using Mann-Whitney for continuous variables and Fishers exact test for categorical variables.
b\*Result indeterminant. \*7/43 unconfirmed HIV status, \*\*3 mothers had missing CD4 data, \*\*\*self-reported exclusive breastfeeding.
811
812
813
814
815

#### 816 Table 2. Robust opsonising and killing function of anti-pneumococcal capsular

#### 817 polysaccharide specific IgG antibodies in infant serum

PCV13	;	HUU infants GMOI	<b>HEU</b> infants		HUU infants	HEU infants	
Seroty	pes	(95% CI)	GMOI (95% CI)		GMC (95% CI)	GMC (95% CI)	
				p-value			p-value
	4	52.70	69.57	0.95	0.52	0.9	0.66
		(12.02 – 231.1)	(8.32 - 581.9)		(0.19-1.42)	(0.2-4.03)	
	бB	39.97	65.58	0.76	0.39	0.55	0.75
		7.27 – 219.6)	(5.72 – 752.1)		(0.2-0.76)	(0.17-1.83)	
1	14	169	223	0.82	0.46	0.84	0.48
		(37.31 – 765.2)	(32.02 - 1553)		(0.2-1.08)	(0.21-3.3)	
2	3F	48.82	78.70	0.80	0.38	0.51	0.99
		(10.19 – 233.9)	(7.61 – 813.5)		(0.18-0.79)	(0.15-1.77)	
6	δA	46.37	74.07	0.72	0.29	0.51	0.32
		(5.9 - 364.3)	(5.68 - 966.9)		(0.16-0.52)	(0.15-1.8)	
9	V	65.79	82.85	0.93	0.4	0.74	0.42
		(11.18 – 387.1)	(9.02 - 761.2)		(0.17-0.91)	(0.19-2.9)	
1	8C	55.35	70.12	0.80	0.71	1.17	0.99
		(11.88 - 258)	(8.6 - 570.9)		(0.24-2.07)	(0.18-7.48)	
1	9F	74.04	92.55	0.93	0.65	1.08	0.49
		(14.81-370.2)	(11.48-746)		(0.3-1.42)	(0.31-3.81)	
	1	11.22	16.39	0.49	2.19	2.5	0.82
		(6.65-18.92)	(6.35-42.26)		(0.96-5.02)	(0.65-9.74)	
	5	17.79	26.98	0.44	0.53	0.62	0.83
		(6.98-45.31)	(7.97-91.28)		(0.23-1.21)	(0.136-2.84)	
7	7F	142.4	117.4	0.87	0.63	1.20	0.66
		(25.17-805.4)	(10.02-1376)		(0.21-1.86)	(0.19-7.50)	
1	9A	23.52	47.49	0.63	1.11	2.31	0.50
		(6.64-83.31)	(5.76-391.3)		(0.33-3.72)	(0.4-13.37)	
	3	22.37	24.31	0.90	0.32	0.56	0.48
		(8.4-59.54)	(6.58-89.82)		(0.15-0.7)	(0.2-1.63)	

818

819 Abbreviations: GMOI (geometric mean opsonophagocytic index), GMC (geometric mean concentration) 95% CI (95% confidence interval),

820 PCV13 (pneumococcal conjugate vaccine 13) The geometric mean opsonic index (GMOI) and 95% confidence intervals (CI) of results are

821 reported for MOPA (HUU n = 11, HEU n = 9); the serotype-specific IgG geometric mean concentration (GMC) (HUU n = 11, HEU n = 8)

for all PCV13 serotypes (1, 3, 4, 5, 6 A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are reported, less than 8 was reported as no response.

012	
025	

### 824 Figure Legends

825	Figure 1. Monocyte phagosomal functional capacity in HEU new-borns and HUU
826	controls. The proportion of CD14+ cells that performed a) phagosomal superoxide burst
827	activity, <b>b</b> ) phagosomal bulk proteolytic activity, <b>c</b> ) and that were associated with beads, <b>d</b> )
828	the phagosomal superoxide burst activity index and <b>e</b> ) the phagosomal bulk proteolytic
829	activity index. The readout for the assay are reported as the median fluorescent intensity of
830	the reporter fluorochrome at 60mins:10mins and 240mins:10mins for oxidative burst and
831	bulk proteolysis, respectively. The activity index was calculated using a ratio of the reporter
832	fluorochrome over the the calibration fluorochrome. Only individuals with an uptake of
833	greater than $\geq$ 30% were used in the phagosomal analysis. Data are presented as medians and
834	analysed using Mann Whitney U test (HUU, n=16; HEU, n=12).
835	
836	Figure 2: Characterisation of B cell immune profiles in HEU and HUU new-borns
837	Cord blood was stained with the following fluorochrome-conjugated antibodies, anti-CD19
838	APC, anti-CD10 PE-Cy7, anti-CD21-FITC and anti-CD27 APC-CY7. Singlets were defined
839	using FSC-A vs. FSC-H parameters and lymphocytes were gated using SSC-A and FSC-A. B
840	cells were then gated using CD19 against SSC-A. a) The proportion of B cell subsets were
841	clasified using CD10, CD21 and CD27 as follows, <b>b</b> ) CD10 <sup>-</sup> CD21 <sup>+</sup> CD27 <sup>-</sup> (naive), CD10 <sup>-</sup>
842	CD21 <sup>-</sup> CD27 <sup>+</sup> (resting memory), CD10 <sup>-</sup> CD21 <sup>+</sup> CD27 <sup>+</sup> (activated memory), CD10 <sup>-</sup> CD21 <sup>-</sup>
843	CD27 <sup>-</sup> (tissue-like memory) and <b>c</b> ) CD10 <sup>+</sup> CD27 <sup>-</sup> (immature transitional).
844	d-e) Expression of CD95e450, FcLR4 PE and PD-1 APC (exhausted and activatory inhibited
845	B-cells) were gated as a proportion of CD19+ cells.
846	Data are presented as medians [IQR] and analysed using Mann Whitney U test (HUU n=42,
847	HEU n=18).

848

849 Figure 3. Characterisation of T cell subsets in HEU and HUU new-borns. a) Whole cord 850 blood was stained with the following fluorochrome-conjugated antibodies, anti-CD3 851 APCCY7, anti-CD4 Pacific Blue, anti-CD8-FITC, anti-CCR7 APC and anti-CD45RA 852 PECY7. Singlets were defined using FSC-A vs. FSC-H parameters and lymphocytes were gated using SSC-A and FSC-A. T cells were then gated using CD3 against SSC-A, then a 853 CD4 versus CD8 plot was used to separate the two main T cell subsets. b)CD4<sup>+</sup> and CD8<sup>+</sup> T 854 855 cell subsets were clasified using CCR7 and CD45RA as follows CCR7-CD45RA- (effector 856 memory), CCR7<sup>+</sup>CD45RA- (central memory), CCR7<sup>+</sup>CD45RA<sup>+</sup> (naïve) and CCR7<sup>-</sup> 857 CD45RA<sup>+</sup>(terminally-differentiated). 858 c) Whole cord blood was stained with the following fluorochrome-conjugated antibodies, 859 anti-CD3 APCCY7, anti-CD4 Pacific Blue, anti-CD8-PECY7 and CD57 FITC, PD1-PE. 860 Singlets were defined using FSC-A vs. FSC-H parameters and lymphocytes were gated using 861 SSC-A and FSC-A. T cells were then gated using CD3 against SSC-A, then a CD4 versus CD8 plot was used to separate the two main T cell subsets. d) CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets 862 863 were clasified using CD57 (senescent) and PD-1 (exhausted). (HUU, n = 36; HEU, n = 25). e) Isolated CBMCs were incubated with PHA or PPD for 18 hours and IFN-y producing cells 864 865 were detected on a 96-well microtitre ELISpot plate. The frequency of SFCs/million CBMCs 866 are plotted for all subjects. (HUU, n =34; HEU, n =22) Data analysed using Fisher's exact 867 test. 868 869 Figure 4: Characterisation of B cell and T cell subsets in HEU and HUU infants 870 Cord blood was stained with the following fluorochrome-conjugated antibodies, anti-CD19

APC, anti-CD10 PE-Cy7, anti-CD21-FITC and anti-CD27 PE. Singlets were defined using

872 FSC-A vs. FSC-H parameters and lymphocytes were gated using SSC-A and FSC-A. B cells

873 were then gated using CD19 against SSC-A. a) The proportion of B cell subsets were

874	clasified using	CD10, CD2	21 and CD2	7 as follows, <b>b</b>	) CD10 <sup>-</sup> C	D21 <sup>+</sup> CD27 <sup>-</sup>	(naive).	CD10
					/		· · · · / /	

875 CD21<sup>-</sup>CD27<sup>+</sup> (resting memory), CD10<sup>-</sup>CD21<sup>+</sup>CD27<sup>+</sup> (activated memory), CD10<sup>-</sup>CD21<sup>-</sup>

876  $CD27^{-}$  (tissue-like memory) and c)  $CD10^{+}CD27^{-}$  (immature transitional).

- 877 Whole blood was stained with the following fluorochrome-conjugated antibodies, anti-CD3
- 878 APCH7, anti-CD4 Pacific Blue, anti-CD8-FITC, anti-CCR7 APC and anti-CD45RA PE.
- 879 Singlets were defined using FSC-A vs. FSC-H parameters and lymphocytes were gated using
- 880 SSC-A and FSC-A. T cells were then gated using CD3 against SSC-A, then a CD4 versus
- 881 CD8 plot was used to separate the two main T cell subsets. **d-e**)CD4<sup>+</sup> and CD8<sup>+</sup> T cell

subsets were clasified using CCR7 and CD45RA as follows CCR7-CD45RA- (effector

883 memory), CCR7<sup>+</sup>CD45RA- (central memory), CCR7<sup>+</sup>CD45RA<sup>+</sup> (naïve) and CCR7<sup>-</sup>

884 CD45RA<sup>+</sup>(terminally-differentiated).

Bata are presented as medians [IQR] and analysed using Mann Whitney U test (HUU n=42,
HEU n=31).

887

888 Figure 5. Infant and maternal antibody responses. Preceding and following Penta-

889 DTwPHibHepB vaccination we measured vaccine titers using an ELISA to **a**) anti-Hib IgG

**b**) anti-TT IgG **c**) anti-DT IgG in infant serum at 5-7 (HUU, n=50; HEU n=39), 14-15 (HUU,

891 n=22; HEU, n=27) and 18-23 (HUU, n=25; HEU, n=19) weeks. HIV- uninfected (n=61) and

HIV-infected (n=43) and maternal titres for d) anti-Hib IgG e) anti-TT IgG f) anti-DT IgG

are depicted. Blue circles are controls and red are HEU infants or HIV-infected mothers.

894 Green dotted horizontal line represents cut-off for protective titers. Data are presented as

- 895 medians and analysed using Mann Whitney U test. Minimum putative protective titres are
- 896 0.15ug/mL (passive) and 1.0ug/mL (acquired) for *Hib*<sup>124</sup>, and 0.01IU/mL for TT <sup>125</sup>and DT
- 897 <sup>126</sup>.
- 898

### 899 Figure 6: Infant exposure to immune modulating viruses HCMV and HIV

e incubated with 15-mer egative control. IFN-γ
egative control. IFN-γ
e. <b>b</b> ) The frequency of
ing Fisher's exact test
c) Plasma anti-CMV IgG
rary titer; blue circles are
ans [IQR] and analysed
on of <b>d</b> ) HUU and HEU
detected CMV DNA in
- n=23, HIV+ n=35). The
nti-EBV IgG in their
e EBNA4 protein by RT-
t test and effective size
hagosomal functional
parameters and
SC-A vs. AF405 to gate
on fluorescent intensity of
an indorescent intensity of

923 bulk proteolysis, respectively. The activity index was calculated using a ratio of the reporter

- 924 fluorochrome over the the calibration fluorochrome. Only individuals with an uptake of
- 925 greater than  $\geq$  30% were used in the phagosomal analysis.
- 926
- 927 Supplementary Figure 2: Gating strategy to characterise B cells. a) Blood was stained
- 928 with the following fluorochrome-conjugated antibodies, anti-CD19 APC, anti-CD10 PE-Cy7,
- 929 anti-CD21-FITC and anti-CD27 PE. Singlets were defined using FSC-A vs. FSC-H
- parameters and lymphocytes were gated using SSC-A and FSC-A. B cells were then gated
- 931 using CD19 against SSC-A. The following populations were determined: CD10<sup>-</sup>
- 932 CD21<sup>+</sup>CD27<sup>-</sup> (naive), CD10<sup>-</sup>CD21<sup>-</sup>CD27<sup>+</sup> (resting memory), CD10<sup>-</sup>CD21<sup>+</sup>CD27<sup>+</sup> (activated
- 933 memory), CD10<sup>-</sup>CD21<sup>-</sup>CD27<sup>-</sup> (tissue-like memory) and c) CD10<sup>+</sup>CD27<sup>-</sup> (immature
- transitional). b) Blood was stained with CD19 PERCP, anti-CD10 PE-Cy7, anti-CD21-FITC
- and anti-CD27 APCCY7, FcRL4 PE, CD95e450 and CD27 APCCY7 to determine B cells
- 936 expressing inhibitory markers.
- 937
- 938

#### 939 Supplementary Figure 3: IFN-γ producing cells to HIV protein GAG at birth

- A 15-mer GAG peptide pool was used to stimulate isolated CBMCs from cord blood in an
- 941 18hour T cell EliSpot assay. IFN-γ producing cells were detected on a 96-well microtitre
- 942 ELISpot plate. **a**) The frequency of GAG SFCs/million CBMCs are plotted for all subjects.
- 943 Data analysed using Fisher's exact test (HUU, n =35; HEU, n=23).
- 944

```
Supplementary Figure 4: Gating strategy to characterise T cell subsets. a)Whole blood
was stained with the following fluorochrome-conjugated antibodies, anti-CD3 APCH7, anti-
CD4 Pacific Blue, anti-CD8-FITC, anti-CCR7 APC and anti-CD45RA PE. b) Cord blood
was stained with the following fluorochrome-conjugated antibodies, anti-CD3 APCY7, anti-
```

949	CD4 Pacific Blue, anti-CD8-PECY7, anti-CCR7 APC and anti-CD45RA PECY5, PD-1 PH
950	and CD57 FITC.

- 951 Singlets were defined using FSC-A vs. FSC-H parameters and lymphocytes were gated using
- 952 SSC-A and FSC-A. T cells were then gated using CD3 against SSC-A, then a CD4 versus
- 953 CD8 plot was used to separate the two main T cell subsets. FMO were used to determine
- gating. CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets were clasified using CCR7 and CD45RA as follows
- 955 CCR7-CD45RA- (effector memory), CCR7<sup>+</sup>CD45RA- (central memory), CCR7<sup>+</sup>CD45RA<sup>+</sup>
- 956 (naïve) and CCR7<sup>-</sup>CD45RA<sup>+</sup>(terminally-differentiated).
- 957

```
958 Supplementary Figure 5: IFN-γ producing cells to vaccine antigens in HEU and HUU
```

- 959 infants
- 960 Detection of IFN-γ producing cells using a T-cell ELISPOT assay in HUU and HEU infants..
- Isolated PBMCs were incubated with either PPD, TT, Hb or PHA as a positive control or
- 962 RPMI media as a negative control for 18 hours. IFN-γ producing cells were detected on a 96-
- 963 well microtitre ELISpot plate. a) The frequency of SFCs/million PBMCs are plotted for all
- 964 subjects. Data analysed using Fisher's exact test (HUU, n =22; HEU, n=34).

965

966 Supplementary Table

967 Supplementary Table 1. Fluorochromes

968

- 969 Supplementary Table 2. Fluorescent antibody panels
- 970



Figure 2





1 PHA PPD









f.



ΗŪU

HEU



HİV-HIV+

## Supplementary Figure 1 – CORD BLOOD



## **Supplementary Figure 2**



со27 АРС-СҮ7

# Supplementary Figure 3 – CORD BLOOD



## **Supplementary Figure 4**

infant blood



b.

Cord blood



## Supplementary Figure 5 - INFANT



# Supplementary Table 1 – Fluorochromes

a.

Marker	Fluorochrome	Clone	Manufacturer	Filter ex/em	lsotype
CD3	APC-H7	SK7 (Leu-4)	BD	640/785	Mouse BALB/c lgG <sub>1</sub> , k
CD4	Pacific Blue	RPA-T4	BD	401/452	Mouse IgG <sub>1</sub> , k
CD8	FITC	RPA-T8	BD	494/520	Mouse IgG <sub>1</sub> , k
CD19	АРС	HIB19	BD	633/650	Mouse IgG <sub>1</sub> , k
CD27	PE	M-T271	BD	496/578	Mouse BALB/c lgG1, k
CD27	АРС-Су7	M-T271	Biolegend	633/	Mouse IgG <sub>1</sub> , k
CD14	PE-Cy7	M5E2	BD	496/785	Mouse IgG2a, k
CD10	PE-Cy7	HI10a	BD	496/785	Mouse BALB/c lgG1, k
CD21	FITC	B-ly4	BD	494/520	Mouse IgG <sub>1</sub> , k
CD45RA	PE	HI100	BD	496/578	Mouse IgG <sub>2b</sub> , k
CCR7	АРС	2-L1-A	BD	650/660	Mouse BALB/c lgG1, k
CD95	efluor450	DX2	eBioscience	405/450	Mouse IgG <sub>1</sub> , k
FcRL4	PE	413D12	Biolegend	496/578	Mouse IgG2 b, k
PD-1	АРС	MIH4	BD	650/660	Mouse IgG1,k
CD57	FITC	Leu-7	BD	494/520	Mouse IgM,k

# Supplementary Table 2 – Fluorescent antibody panels

a.

Panel 1	Panel 2	Panel 3	Panel 4	Panel 5
anti-CD14 Phyocoerythrin Cyanine-7 (PECy7)	anti-CD19 Allophycocyani n (APC)	anti-CD19 Peridinin- Chlorophyll- Protein (PERCP)	anti-CD3 Allophycocyanin- H7 (APC-H7)	anti-CD3 Allophycocyanin -H7 (APC-H7)
anti-AF405 Beads	anti-CD10 PE- Cy7	anti-CD10 PE-Cy7	anti-CD4 Pacific Blue (PB)	anti-CD4 Pacific Blue (PB)
	anti-CD21 FITC	anti-CD21 FITC	anti-CD8 Fluorescein (FITC)	anti-CD8 (PECY7)
	anti-CD27 (PE)	anti-CD27 APC- Cy7	anti-CD45RA Phyocoerythrin (PE)	anti-CD45RA PECY5
		anti-CD95 e450	anti-CCR7 Allophycocyanin (APC)	anti-CD57 FITC
		anti-FcLR4 PE		anti-PD-1 PE
		anti-PD - 1 APC		